Brind.

Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.

Steady: 0 in the last 7 days Updated sep 14

The latest in this situation

  1. GSK is submitting data to the FDA regarding potential expansion of its drug indications.

How it started

2 reports, 2 independent, last reported Sep 3. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.

Who's involved

What this event is mainly about
FDAGSKHoffmann-La Roche

How it developed

Newest first. Tap a step to see who reported it.
  1. GSK is submitting data to the FDA regarding potential expansion of its drug indications.Sub-event
  2. GSK's drug validation process is being influenced by FDA guidance, with ties to the U.K. operations.1 source
  3. GSK has launched a competing ROS1 therapy, while Nuvation Bio Inc. presented relevant data at a major medical conference.Sub-event
  4. GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.Sub-event
  5. Harmony, IDEAYA, and Hoffmann-La Roche partnered to study combination therapy for pancreatic cancer using machine learning.Sub-event
  6. GSK is involved in competitive challenges regarding lung cancer treatments while awaiting FDA decisions.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped